Literature DB >> 29853478

Sex Differences at the Time of Myectomy in Hypertrophic Cardiomyopathy.

Louise L A M Nijenkamp1, Ilse A E Bollen1, Hannah G van Velzen2, Jessica A Regan1, Marjon van Slegtenhorst3, Hans W M Niessen4, Arend F L Schinkel2, Martina Krüger5, Corrado Poggesi6, Carolyn Y Ho7, Diederik W D Kuster1, Michelle Michels2, Jolanda van der Velden8,9.   

Abstract

BACKGROUND: One of the first clinically detectable alterations in heart function in hypertrophic cardiomyopathy (HCM) is a decline in diastolic function. Diastolic dysfunction is caused by changes in intrinsic properties of cardiomyocytes or an increase in fibrosis. We investigated whether clinical and cellular parameters of diastolic function are different between male and female patients with HCM at the time of myectomy. METHODS AND
RESULTS: Cardiac tissue from the interventricular septum of patients with HCM (27 women and 44 men) was obtained during myectomy preceded by echocardiography. At myectomy, female patients were 7 years older than male patients and showed more advanced diastolic dysfunction than men evident from significantly higher values for E/e' ratio, left ventricular filling pattern, tricuspid regurgitation velocity, and left atrial diameter indexed for body surface. Whereas most male patients (56%) showed mild (grade I) diastolic dysfunction, 50% of female patients showed grade III diastolic dysfunction. Passive tension in HCM cardiomyocytes was comparable with controls, and myofilament calcium sensitivity was higher in HCM compared with controls, but no sex differences were observed in myofilament function. In female patients with HCM, titin was more compliant, and more fibrosis was present compared with men. Differences between female and male patients with HCM remained significant after correction for age.
CONCLUSIONS: Female patients with HCM are older at the time of myectomy and show greater impairment of diastolic function. Furthermore, left ventricular and left atrial remodeling is increased in women when corrected for body surface area. At a cellular level, HCM women showed increased compliant titin and a larger degree of interstitial fibrosis.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  body surface area; cardiomyopathy, hypertrophic; diastole; humans; sex

Mesh:

Year:  2018        PMID: 29853478     DOI: 10.1161/CIRCHEARTFAILURE.117.004133

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  14 in total

1.  Sex-related differences in left ventricular remodeling and outcome after alcohol septal ablation in hypertrophic obstructive cardiomyopathy: insights from cardiovascular magnetic resonance imaging.

Authors:  You-Zhou Chen; Xing-Shan Zhao; Jian-Song Yuan; Yan Zhang; Wei Liu; Shu-Bin Qiao
Journal:  Biol Sex Differ       Date:  2022-07-07       Impact factor: 8.811

2.  Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy.

Authors:  Larissa M Dorsch; Maike Schuldt; Cristobal G dos Remedios; Arend F L Schinkel; Peter L de Jong; Michelle Michels; Diederik W D Kuster; Bianca J J M Brundel; Jolanda van der Velden
Journal:  Cells       Date:  2019-07-18       Impact factor: 6.600

3.  End-diastolic force pre-activates cardiomyocytes and determines contractile force: role of titin and calcium.

Authors:  Aref Najafi; Martijn van de Locht; Maike Schuldt; Patrick Schönleitner; Menne van Willigenburg; Ilse Bollen; Max Goebel; Coen A C Ottenheijm; Jolanda van der Velden; Michiel Helmes; Diederik W D Kuster
Journal:  J Physiol       Date:  2019-07-30       Impact factor: 5.182

4.  Effect of body surface area and gender on wall thickness thresholds in hypertrophic cardiomyopathy.

Authors:  R Huurman; A F L Schinkel; N van der Velde; D J Bowen; M E Menting; A E van den Bosch; M van Slegtenhorst; A Hirsch; M Michels
Journal:  Neth Heart J       Date:  2020-01       Impact factor: 2.380

5.  Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy.

Authors:  Jolanda van der Velden; Diederik W D Kuster; Maike Schuldt; Jiayi Pei; Magdalena Harakalova; Larissa M Dorsch; Saskia Schlossarek; Michal Mokry; Jaco C Knol; Thang V Pham; Tim Schelfhorst; Sander R Piersma; Cris Dos Remedios; Michiel Dalinghaus; Michelle Michels; Folkert W Asselbergs; Marie-Jo Moutin; Lucie Carrier; Connie R Jimenez
Journal:  Circ Heart Fail       Date:  2021-01-12       Impact factor: 8.790

6.  Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy.

Authors:  Maike Schuldt; Larissa M Dorsch; Jaco C Knol; Thang V Pham; Tim Schelfhorst; Sander R Piersma; Cris Dos Remedios; Michelle Michels; Connie R Jimenez; Diederik W D Kuster; Jolanda van der Velden
Journal:  Front Cardiovasc Med       Date:  2021-03-01

7.  Sex differences in the prognosis of patients with hypertrophic cardiomyopathy.

Authors:  Minkwan Kim; Bongsung Kim; You-Jung Choi; Hyun-Jung Lee; Heesun Lee; Jun-Bean Park; Seung-Pyo Lee; Kyung-Do Han; Yong-Jin Kim; Hyung-Kwan Kim
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

Review 8.  Untying the knot: protein quality control in inherited cardiomyopathies.

Authors:  Larissa M Dorsch; Maike Schuldt; Dora Knežević; Marit Wiersma; Diederik W D Kuster; Jolanda van der Velden; Bianca J J M Brundel
Journal:  Pflugers Arch       Date:  2018-08-14       Impact factor: 3.657

9.  Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy.

Authors:  Ethan J Rowin; Martin S Maron; Sophie Wells; Parth P Patel; Benjamin C Koethe; Barry J Maron
Journal:  J Am Heart Assoc       Date:  2019-10-30       Impact factor: 5.501

10.  Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants.

Authors:  Rahana Y Parbhudayal; Hendrik J Harms; Michelle Michels; Albert C van Rossum; Tjeerd Germans; Jolanda van der Velden
Journal:  J Am Heart Assoc       Date:  2020-04-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.